NCT00491517View on ClinicalTrials.gov

Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

August 31, 2009

Conditions
Polycystic Kidney
Interventions
DRUG

Sirolimus

Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.

DRUG

conventional therapy

Antihypertensive drugs for patients with high blood pressure.

Trial Locations (1)

Unknown

"Hospital Azienda Ospedaliera Ospedali Riuniti di Bergamo Unit of Neprology and Dialysis", Bergamo

All Listed Sponsors
lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT00491517 - Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety | Biotech Hunter | Biotech Hunter